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osting by E
cense.Abstract Simple, sensitive and accurate thin layer procedure was described for a quantitative
determination of paracetamol in its bulk powder and in its pharmaceutical dosage forms in the pres-
ence of its degradation product. The method consists of dissolving the drug in methanol and then
spotting the solution on a thin layer of silica gel G254. Paracetamol was separated on silica gel using
the mixture of the mobile phase, ethyl acetate: benzene: acetic acid in a ratio (1:1:0.05 v/v/v).
Absorbance measurements (detection of reﬂectance) of the separated drug were carried out at
250 nm. Calibration curves were established in the concentration range of 5–20 mcg/spot for para-
cetamol. Quantitation is achieved by comparing the area under the peaks obtained from scanning
the thin layer chromatographic plates in a spectrodensitometer. The method has been successfully
applied to pharmaceutical preparations (capsules) and the results obtained were statistically com-
pared with those obtained by applying the reference method.
ª 2010 King Saud University. Open access under CC BY-NC-ND license.1. Introduction
Paracetamol (acetaminophen, (N-acetyl-p-amino,phenol),4-
acetamidophenol) is widely used as a minor analgesic (Bloom-
ﬁeld, 2002). The structural formula of paracetamol is shown in
Fig. 1.o.com
ity.
lsevierThe analgesic action is mainly used as an alternative to
aspirin without the side effect of salicylate on gastric mucosa.
The determination of paracetamol and its quality control are
of vital importance because of the increasing therapeutic use.
Paracetamol is very widely used analgesic drug formulated in
a variety of dosage forms. The most common formulation is
tablets, generally containing 500 mg paracetamol. Paraceta-
mol and chlorzoxazone are used in association for myorelax-
ation and analgesic purposes (Goyal and Singh, 2006).
p-Amino phenol is the primary hydrolytic degradation prod-
uct of paracetamol. Generally paracetamol does not exhibit
any harmful side effects but hypersensitivity or overdose in
few cases leads to the formation of hepatotoxic and nephro-
toxic metabolites. Thus it is very important to have an ana-
lytical technique for the determination of intact paracetamol
HO NH
H3C
O
Figure 1 The structural formula of paracetamol.
342 N.M. Mostafain presence of its degradation product or in presence of other
drugs in its pharmaceutical formulation. Several methods
have been reported for the analysis of paracetamol namely
electrochemical (Pejic et al., 2006; Christie et al., 1993; Fogg
et al., 1970), voltametric (Goyal et al., 2005; Navarro et al.,
1988), spectrophotometric (Filik et al., 2005; Xu and Li,
2004; Dinc et al., 2001, 2002; Afshari and Lui, 2001; Erk
et al., 2001; Rodenas et al., 2000; Nagaraja et al., 1998;
Morelli, 1989), ﬂow injection (Ruengsitagoon et al., 2006;
Knochen et al., 2003; Medina et al., 1999), spectroﬂuorimet-
ric (Oliva et al., 2005; Moreira et al., 2005; Vilchez et al.,
1995), chromatographic (Chen et al., 2005; Jensen et al.,
2004; Nagaralli et al., 2003; Franeta et al., 2002), electropho-
resis (Heitmeier and Blaschke, 1999) and titrimetric methods
(Kumar and Letha, 1997).
The present work describes a densitometric method to
determine paracetamol in bulk and in dosage forms based on
separation on silica gel plates and scanning of the developed
quenched zones by TLC densitometer.
2. Experimental
Samples
– Paracetamol, bulk powder, Sigma (UK). It was analysed by
reference method (Juddin et al., 2007) and found to be
99.93 ± 0.25.
– Chlorzoxazone, bulk powder obtained from Amon Phar-
maceutical, Cairo, ARE.
– p-Amino phenol, Merck.
– Relaxone capsules labeled to contain 300 mg paracetamol
and 250 mg chlorzoxazone, batch No. HHo79 manufac-
tured by Jamjoom Pharma, KSA.
– Parafon capsules labeled to contain 300 mg paracetamol
and 250 mg chlorzoxazone, batch No. 7858 manufactured
by Riyadh Pharma, KSA.
Reagents
– All the chemicals and solvents used were of analytical
grade:
– Methanol, Merck.
– Benzene, Prolabo.
– Ethyl acetate, Prolabo.
– Acetic acid, Merck.
Apparatus
– Shimadzu CS 9301, dual wavelength scanning densitometer.
– Precoated glass TLC plates, silica gel 60 (20 · 20 cm with-
out ﬂuorescent indicator), thickness 0.25 mm (Alugram,
Germany).
– Hamilton micro syring, 10 lL.
– Chromatographic jars, 15 · 20 · 30 cm dimensions.2.1. Procedures
2.1.1. TLC – densitometric determination of paracetamol bulk
powder
Prepare stock solution of paracetamol containing 5 mg ml1 in
methanol by dissolving 0.5 g of paracetamol in 100 ml of meth-
anol. Take 1, 2, 3 and 4 ml of paracetamol stock solution
(5 mg ml1) into 10 ml volumetric ﬂasks and complete to vol-
ume with methanol. The concentrations of the last working
solutions were 0.5, 1, 1.5 and 2 mg ml1. Apply 10 lL of each
of the working standard solutions of paracetamol to thin layer
chromatographic plates.
Spots were spaced 2 cm apart from each other and 2 cm
from the bottom edge of the plate. After drying, the plates
were placed in a chromatographic tank previously saturated
for 1 h with a mobile phase which consists of ethyl acetate:
benzene: acetic acid (1:1:0.05 v/v/v). The plates were developed
by ascending chromatography through a distance of 18 cm,
dried at room temperature and the spots were detected under
UV lamp (254 nm) as dark quenched zones.
2.1.2. Scanning of each spot was done under the following
conditions
– Photo mode: reﬂection.
– Scan mode: zigzag.
– Chart speed: 50 mm min1.
– Wavelength: 250 nm (Rf = 0.32).Recorder parameters:
– Abscissa scale: ·1.
– Result out put: chromatogram and area under the peak.
Peak detection:
– Minimum width: 10 mm.
– Swing width: 8 mm.The calibration curve representing the relation between the
recorded area under the peaks and the corresponding concen-
trations was plotted. Linear relationship was obtained over
paracetamol concentration range 5–20 mcg/spot. The regres-
sion equation was computed and found to be Y= 0.41C
 0.002 where Y is the area under the peak · 103 and C is
the concentration in mcg/spot. The concentration of paraceta-
mol bulk powder was calculated from its corresponding regres-
sion equation and the results obtained are shown in Table 1.
2.2. Application of the proposed methods for the determination
of intact paracetamol in presence of its degradation product
An accurately aliquot portions (9–1 ml) of intact paracetamol
stock solution (5 mg ml1) in methanol were mixed with (1–
9 ml) of degraded paracetamol (p-amino phenol) (5 mg ml1)
in methanol, so that the ﬁnal volume of the solution was
10 ml containing (10–90%) of degradation product. The pro-
cedure is followed as mentioned above under Section 2.1.
2.3. Application of the proposed methods for the determination
of paracetamol in presence of chlorzoxazone
An accurately aliquot portions (9–1 ml) of intact paracetamol
stock solution (5 mg ml1) in methanol were mixed with
Figure 2 Spectrodensitometric chromatogram of paracetamol in
methanol at 250 nm.
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Figure 3 Linearity of area under the peak to concentration of
paracetamol.
Table 1 Regression equation data and quantitative determination of paracetamol by TLC densitometric method.
Sample Rf kmax Linearity range (mcg/spot) Intercept
a Slopea Correlation coeﬃcienta Recovery (%)
Paracetamol 0.32 250 5–20 0.002 0.41 0.999 100.06 ± 0.22
P. aminophenol 0.45
Chlorzoxazone 0.76
a Regression equation, y= bc - a, where y is the area under the peak, c is the concentration in mcg, b is the slope and a is the intercept.
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ﬁnal volume of the solution was 10 ml containing (10–90%) of
chlorzoxazone. The procedure is followed as mentioned above
under Section 2.1.
2.4. Application of the proposed methods for the determination
of paracetamol in their pharmaceutical formulations
2.4.1. Relaxone capsules
The above mentioned procedure was optimized for the deter-
mination of paracetamol concentration in the capsule prepara-
tion, where 20 capsules of relaxone were evacuated, mixed and
weighed and the average weight of each capsule was calcu-
lated. A quantity of powders equivalent to 0.02–0.05 g of par-
acetamol were transferred into a series of 100 ml volumetric
ﬂask. Add 75 ml of methanol, shake for 10 min and complete
to volume with methanol. The solution was ﬁltered and then
proceed as mentioned above (Section 2.1) for the determina-
tion of paracetamol (Rf = 0.32) at 250 nm.
2.4.2. Parafon capsules
The above mentioned procedure was optimized for the deter-
mination of paracetamol concentration in capsule preparation,
where 20 capsules of parafon were evacuated, mixed and
weighed and the average weight of each capsule was calcu-
lated. A quantity of powder equivalent to 0.02–0.05 g of para-
cetamol was transferred into 50 ml volumetric ﬂasks. Add
75 ml methanol, shake for 10 min and complete to volume
with methanol. The solution was ﬁltered and then proceed as
mentioned above (Section 2.1) for the determination of para-
cetamol (Rf = 0.32) at 250 nm.
3. Results and discussion
The present work is concerned with the application of TLC
densitometric technique for the determination of paracetamol
in pure form and in its pharmaceutical dosage form. The meth-
od depends on the difference in Rf values of the intact drug
degraded drug (p-amino phenol) and chlorzoxazone. The pro-
cedure depends on separation of the drugs using a suitable
developing system and determining Rf values of the separated
drugs. Then quantitative determination of the separated para-
cetamol is done by scanning the chromatographed zones by
TLC densitometer, where the drug was determined as
quenched zones on silica gel plates.
Developing system of ethyle acetate: benzene: acetic acid
(1:1:0.05 v/v/v) was found suitable mobile phase for complete
separation of paracetamol (Rf = 0.32), Fig. 2.
The chromatoplates were quantitatively evaluated at
250 nm for paracetamol. Optimized conditions including satu-
ration time, spotting time, developing distance, volume of the
developing system, drying time and scanning parameters, wereﬁxed for all runs of the procedure. By applying this technique a
linear relation correlation was obtained between the area un-
der the peak and the concentration (5–20 mcg/spot) for para-
cetamol, Fig. 3.
Linear regression equation were computed and used for
the determination of the drug under the optimized conditions.
The accuracy and precision of the method were determined by
Table 2 Spectrodensitometric determination of paracetamol in pharmaceutical formulations and application of standard addition
technique.
Mixture (1)a recovery% Mixture (2)b recovery% Pharmaceutical dosage forms
recovery (%)
Standard addition technique
recovery (%)
98.72 ± 2.02 99.65 ± 0.75 Relaxone Parafon Relaxone Parafon
99.40 ± 0.62 99.41 ± 0.23 99.26 ± 0.46 98.94 ± 0.93
a Paracetamol mixed with degradation product.
b Paracetamol mixed with chlorzoxazone.
Table 3 Statistical comparison between the results of the
proposed method and the pharmacopoeial method.
Paracetamol Proposed method Reference method
(Juddin et al., 2007)
Mean ± S.D 100.06 ± 0.22 99.93 ± 0.25
n 4 6
Variance 0.0484 0.0625
Student t(0.95) test 0.23 (1.860)
F ratio (0.01) 1.29 (9.2)
344 N.M. Mostafathe analysis of standard solutions of the drug in different con-
centrations. The results given in Table 1 show that the recov-
ery of paracetamol was 100.06 ± 0.22.
The applicability of the TLC densitometric method for the
assay of pharmaceutical preparations was examined by analys-
ing relaxone and parafone capsules. The average percentages
recovery were found to be 99.40 ± 0.62 and 99.41 ± 0.23,
respectively, Table 2. The validity study of the proposed
TLC densitometric method was checked by applying the stan-
dard addition technique, where the authentic was added to a
known amount of sample solutions of capsules which has been
analysed before. The recovery of the authentic added was in
the range of 99.26 ± 0.46 (for relaxone capsules) and 99.94
± 0.93 (for parafone capsules). This conﬁrms a non-interfer-
ence of exicipients and additive used in capsules.
The results of analysis of reference samples of paracetamol
where compared by the reference method which depends on
photo-absorption of the drug at 243 nm in water (Juddin
et al., 2007). Table 3 shows a statistical comparison between
the results of TLC densitometric method and the reference
method of the drug. The calculated ‘‘t’’ and ‘‘F’’ values were
less than the corresponding theoretical values and there was
no signiﬁcant difference between the two methods with respect
to both precision and accuracy.
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